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Abstract 22 
Multidrug resistance is a widespread problem among various diseases and cancer is no exception. 23 
We had previously described the chemo-sensitizing activity of ecdysteroid derivatives with low 24 
polarity on drug susceptible and multi-drug resistant (MDR) cancer cells. We have also shown 25 
that these molecules have a marked selectivity towards the MDR cells. Recent studies on the 26 
oximation of various steroid derivatives indicated remarkable increase in their antitumor activity, 27 
but there is no related bioactivity data on ecdysteroid oximes. In our present study, 13 novel 28 
ecdysteroid derivatives (oximes, oxime ethers and a lactam) and one known compound were 29 
synthesized from 20-hydroxyecdysone 2,3;20,22-diacetonide and fully characterized by 30 
comprehensive NMR techniques revealing their complete 1H and 13C signal assignments. The 31 
compounds exerted moderate to strong in vitro antiproliferative activity on HeLa, SiHa, MCF-7 32 
and MDA-MB-231 cell lines.  Oxime and particularly oxime ether formation strongly increased 33 
their inhibitory activity on the efflux of rhodamine 123 by P-glycoprotein (P-gp), while the new 34 
ecdysteroid lactam did not interfere with the efflux function. All compounds exerted potent 35 
chemo-sensitizing activity towards doxorubicin on a mouse lymphoma cell line and on its MDR 36 
counterpart, and, on the latter, the lactam was found the most active. Because of its MDR-37 
selective chemo-sensitizing activity with no functional effect on P-gp, this lactam is of high 38 
potential interest as a new lead for further antitumor studies. 39 
 40 
Keywords: Ecdysterone; semi-synthesis; Beckmann-rearrangement; chemotherapy; adjuvant; p-41 
glycoprotein; efflux pump inhibitor  42 
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Introduction 43 
Synthetic modification of steroidal compounds remains a promising strategy in the hunt for novel 44 
drug candidates since even minor changes in the substitution pattern of their chemical backbone 45 
may significantly modify specific bioactivities. Certain steroidal oximes and oxime ethers were 46 
shown to have antioxidant,[1] antimicrobial,[1] antineoplastic[2] or neuromuscular blocking[3] 47 
activities.  48 
Currently, the antitumor activity of steroid oximes is by far the most deeply investigated and has 49 
recently attracted great scientific attention. For example, oximes and lactams of cholest-4-en-6-50 
one were tested on two human cancer cell lines and were shown to have very high, tumor 51 
selective anticancer activity on HeLa cells.[4] Another study on the structure-activity relationships 52 
(SAR) of hydroxyiminosteroids bearing the oxime group on the steroid A and/or B ring showed 53 
that a C-6 oxime function is preferential over a 6-keto group concerning in vitro cytotoxic 54 
activity of these type of compounds.[5] In a follow-up study on the same compounds, the 55 
importance of 3- and 6-hydroxy functions was highlighted.[6] Furthermore, a set of in vitro 56 
experiments on 63 novel estrone 16-oximes and oxime ethers revealed two oximes as promising 57 
antiproliferative agents with selectivity towards HeLa cells; the compounds modulated cell cycle 58 
and induced apoptosis through caspase-3.[7] In a most recent study, a series of steroidal oximes 59 
and lactams were described to possess significant in vitro antiproliferative activity, and a 6,23-60 
dioxime derivative, obtained from diosgenin acetate, was identified to be the most effective.[8] 61 
Several further recent reports can be found in the literature where well-defined mechanistic 62 
changes could also be connected to the increase in the antiproliferative activity observed after 63 
introducing an oxime moiety into an oxo-compound. For example, a number of α,β-unsaturated, 64 
cyclohexanone-based oximes showed greatly increased activity as compared to their parental 65 
oxo-compounds against BRAFV600E (the most common mutation in the v-raf murine sarcoma viral 66 
oncogenes homolog B1, involved in carcinogenesis and cancer agressiveness) and/or epidermal 67 
growth factor receptor TK kinases (involved in cell proliferation, evasion of apoptosis and 68 
invasive capacity),[9] or focal adhesion kinase (FAK; involved in stimulating metastasis and 69 
tumor progression)[10]. These reports suggest that the preparation of oxime derivatives from 70 
ketosteroids, and particularly from those with an α,β-enone moiety, should be a reasonable 71 
strategy to extend the chemical space towards new, potentially antitumor compounds. 72 
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Ecdysteroids are α,β-unsaturated 6-ketosteroids that occur in a wide range of plant species; as 73 
analogs of the insect molting hormone ecdysone, these compounds possess several biological 74 
functions in the flora and the fauna.[11][12] Since the isolation of the most abundant ecdysteroid 75 
20-hydroxyecdysone (20E), these compounds were reported to also exert various, beneficial 76 
bioactivities in mammals.[13][14][15][16] Additionally, our group revealed that relatively apolar 77 
ecdysteroids can strongly sensitize cancer cells to chemotherapeutics (i.e. “chemo-sensitizing” 78 
activity), and suggested 20-hydroxyecdysone 2,3:20,22-diacetonide (1) as a promising anticancer 79 
lead compound.[17] Interestingly, this sensitization towards various chemotherapeutics could be 80 
observed both on multi-drug resistant (MDR) and drug susceptible cancer cell lines.[18] After 81 
several further studies, exploring this particular anticancer activity of ecdysteroids, we now know 82 
that 1) apolar substituents on the 2,3-diol moiety are more important than those at positions 20 83 
and 22,[19] and 2) an oxidative side-chain cleavage knocks out the inhibitory activity on the efflux 84 
function of P-glycoprotein (P-gp) while maintaining MDR selective sensitizing activity towards 85 
doxorubicin.[20] Regarding semi-synthetic modifications accompanied by the inclusion of 86 
heteroatoms, a difluorinated derivative of 20E 2,3;20,22-diacetonide was found to be a stronger 87 
P-gp inhibitor than its parental molecule (compound 1), while, surprisingly, MDR selectivity of 88 
the difluorinated compound was lower: it sensitized a P-gp expressing MDR cell line to 89 
doxorubicin similarly to its parental compound 1, and a stronger effect than that of 1 was 90 
observed on a non-MDR cell line.[21] The chemical structures of 20E and compound 1 are shown 91 
in Figure 1. 92 
 93 
 94 
Figure 1. Chemical structures of 20-hydroxyecdysone (20E) and 20-hydroxyecdysone 2,3;20,22-95 
diacetonide (1). 96 
 97 
Galyautdinov et al. have previously reported the successful preparation of several (E/Z)-isomeric 98 
ecdysteroid 6-oxime and some lactam derivatives.[22] Considering the above mentioned antitumor 99 
potential of steroidal oximes and the fact that no studies are available on the bioactivity of 100 
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ecdysteroid oximes or lactams, the aim of the present work was to prepare a series of such 101 
compounds, and study their in vitro antitumor potential with a focus on their chemo-sensitizing 102 
activity. 103 
 104 
Results and Discussions 105 
Chemistry 106 
20-hydroxyecdysone 2,3;20.22-diacetonide 1 and its 6-oxime and lactam derivatives were 107 
synthesized following previously published procedures.[22][23] Briefly, compound 1 was reacted 108 
with hydroxylamine or, aiming to prepare new oxime ethers, an alkoxylamine in pyridine at 109 
70°C. A total of 14 nitrogen-containing derivatives were prepared this way (Scheme 1). 110 
 111 
Scheme 1. Synthesis of oxime and oxime ether derivatives of 20-hydroxyecdysone 2,3;20,22-112 
diacetonide.  113 
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Reagents and conditions: a) pyridine, NH2OH·HCl, 70°C, 3 days; b) pyridine, NH2OR·HCl 115 
(mass equiv of 1; R=Me, Et, Allyl, or tBut), 70°C, 24 h; work-up with KOH in anhydrous 116 
MeOH. 117 
 118 
Following each reaction, neutralization with KOH dissolved in anhydrous methanol was utilized 119 
with the aim of obtaining several different, structurally diverse and potentially bioactive products, 120 
including mixtures of 14,15-anhydro- and intact oxime derivatives: the oximes 2 and 3, and 121 
oxime ethers with different 6-O-alkyl substituents 5-15, respectively, were obtained through this 122 
method. Our results confirm previous observations that ecdysteroid 6-oximation can result in 3 123 
different types of product mixtures depending on the neutralization procedure:[22] a mixture of 124 
14,15-anhydro (E/Z)-isomeric oxime pairs form if the reaction does not include a neutralization 125 
step; a 2-4 components mixture of both intact and 14OH-eliminated derivatives is obtained if 126 
alkali dissolved in anhydrous methanol is added; and a mixture of intact (E/Z)-isomeric oxime 127 
pair with retained 14-OH groups is obtained if the neutralizing alkali is dissolved in anhydrous 128 
ethanol. 129 
A second transformation involving the Beckmann-rearrangement of the (6E)-oxime compound 2 130 
was performed utilizing p-toluenesulfonyl chloride (TsCl) in acetone in the presence of sodium 131 
carbonate to obtain a new ecdysteroid derivative, compound 4, with a seven-membered lactam 132 
ring (Scheme 2). As expected, the (6Z)-oxime compound did not form the corresponding lactam 133 
but a tosylate was obtained (not presented, for more details see also reference [23]). 134 
 135 
Scheme 2. Beckmann rearrangement of ecdysteroid (6E)-oxime 2 into lactam 4. 136 
  137 
Reagents and conditions: c) acetone, p-toluenesulfonyl chloride (TsCl, 2 equiv of oxime 2), 138 
Na2CO3 (1 equiv of oxime 2), RT, 6 h. 139 
 140 
Structure elucidation 141 
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We have recently reported the structure elucidation and complete 1H and 13C signal assignment of 142 
a series of dioxolane derivatives of 20-hydroxyecdysone. [19][20][21][24] Here we discuss the 143 
complete 1H and 13C signal assignment of the corresponding 6-oxime and 6-oxime ether 144 
derivatives.  145 
The structure and NMR signals of the products were assigned by comprehensive one- and two-146 
dimensional NMR methods, such as 1H, 13C, DEPTQ, gradient-selected COSY, edited HSQC, 147 
HMBC, ROESY (Rotating frame Overhauser Enchancement Spectroscopy) spectra and 1D-148 
selective variants thereof. It is worth mentioning that due to the molecular mass (500-700 149 
Daltons) the signal/noise value of the selective ROE experiments strongly exceeds that of the 150 
selective NOEs. 151 
To facilitate the comparison of NMR signals of structurally analogous hydrogen and carbon 152 
atoms of the starting compound 1 with those of the 6-oxime 2, and of its Beckmann rearranged 153 
product 4 and 6-oxime-ether derivatives 5 – 15, we applied the usual steroid numbering, and for 154 
the central atoms of the 2,3;20,22-diacetonide moieties C-28 and C-29, respectively. The 13C 155 
chemical shifts of compounds 1, 2 and 4-15 in methanol-d4 are compiled in Table 1. The 156 
characteristic 1H data of compounds with a ∆14,15 C=CH ethylene moiety 2, 4 and 11-15 are 157 
summarised in Table 2, whereas that of the HO-C(14) derivatives 5-10 are shown in Table 3. 158 
  159 
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Table 1. 13C chemical shifts of compounds 2, 4–15 as compared to that of their parental compound 1 (20-160 
hydroxyecdysone 2,3;20,22-diacetonide)[21]; in methanol-d4. 161 
No. 1 2 4
a
 5 6 7 8 9 10 11 12 13 14 15 
1 39.0 39.5 43.2 39.7 39.7 39.4 39.7 39.4 39.8 39.1 39.1 39.1 39.3 39.5 
2 73.7 73.4 73.2 73.6 73.6 73.6 73.6 73.6 73.7 73.4 73.5 73.5 73.6 73.6 
3 73.3 74.0 75.5 74.0 74.0 73.9 74.0 73.8 74.2 73.7 73.8 73.8 74.0 74.1 
4 27.9 30.3 30.9 30.0 30.0 27.0 29.9 27.0 30.0 27.3 27.2 27.2 27.3 30.4 
5 52.7 43.5 56.6 43.8 43.8 38.6 43.8 38.7 44.0 38.4 38.5 38.6 38.2 43.7 
6 205.8 157.0 170.6 157.2 156.9 160.3 157.4 160.7 155.7 160.8 160.6 161.0 159.4 155.8 
7 122.0 110.0 119.9 110.7 110.9 117.5 110.8 117.3 111.3 117.0 117.2 117.0 118.3 110.8 
8 167.1 151.5 151.6 154.1 153.8 150.7 154.1 151.0 152.3 151.0 151.1 151.1 151.3 151.6 
9 35.9 40.2 45.9 35.5 35.5 34.4 35.5 34.4 35.7 39.1 39.2 39.2 39.2 40.2 
10 38.9 38.0 40.7 37.8 37.7 37.0 37.7 37.0 37.6 37.1 37.1 37.1 37.0 37.9 
11 21.8 21.9 25.4 21.5 21.5 21.5 21.5 21.5 21.5 21.8 21.8 21.9 21.9 21.9 
12 32.5 41.3 42.4 32.6 32.6 32.5 32.6 32.5 32.6 41.1 41.1 41.1 41.2 41.3 
13 48.7 49.0 50.2 49.0 48.6 48.3 48.6 48.3 48.6 48.6 48.6 48.7 48.6 48.7 
14 85.4 144.3 154.4 85.9 85.9 85.7 85.9 85.7 86.0 142.4 142.1 142.4 140.6 143.8 
15 31.8 125.3 125.6 32.0 32.0 32.1 32.0 32.1 32.0 124.4 124.3 124.4 123.6 125.0 
16 22.6 32.4 32.6 22.6 22.6 22.7 22.6 22.6 22.6 32.3 32.3 32.4 32.3 32.4 
17 50.6 59.0 59.3 50.6 50.6 50.7 50.6 50.7 50.6 58.9 58.9 59.0 59.0 59.1 
18 17.8 19.7 19.6 18.0 18.0 18.0 18.0 18.0 18.1 19.6 19.6 19.6 19.6 19.7 
19 24.2 23.9 18.1 24.3 24.3 24.3 24.3 24.3 24.3 24.1 24.0 24.1 24.1 24.9 
20 86.0 84.9 84.7 86.0 86.0 86.1 86.0 86.1 86.0 84.9 84.9 85.0 85.0 84.9 
21 22.8 22.0 21.9 22.7 22.7 22.7 22.7 22.7 22.7 22.0 22.0 22.0 22.0 22.0 
22 83.5 83.1 83.1 83.4 83.4 83.4 83.4 83.4 83.4 83.2 83.2 83.2 83.2 83.2 
23 24.9 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.8 24.9 24.9 24.9 
24 42.4 42.1 42.1 42.3 42.3 42.4 42.3 42.4 42.3 42.1 42.1 42.1 42.1 42.7 
25 71.3 71.2 71.2 71.2 71.2 71.2 71.2 71.2 71.2 71.1 71.2 71.2 71.2 71.2 
26 29.1 29.0 29.1 29.1 29.1 29.1 29.1 29.1 29.1 29.1 29.0 29.0 29.0 29.0 
27 29.0 29.7 29.6 29.6 29.6 29.6 29.6 29.5 29.6 29.7 29.7 29.7 29.7 29.7 
28 109.6  109.5 109.4 109.3 109.3 109.3 109.3 109.3 109.3 109.3 109.3 109.2 109.4 
28Meα 26.8  26.6 26.8 26.8 26.8 26.8 26.8 26.9 26.8 26.7 26.7 26.7 26.8 
28Meβ 29.0  28.9 29.0 29.0 29.0 29.0 29.0 29.0 29.1 29.0 29.0 29.0 29.0 
29 108.2  108.0 108.1 108.0 108.1 108.0 108.1 108.0 108.0 108.0 108.1 108.0 108.1 
29Meα 29.5  29.3 29.5 29.5 29.5 29.5 29.4 29.5 29.4 29.4 29.4 29.4 29.4 
29Meβ 27.3  27.3 27.3 27.3 27.3 27.4 27.3 27.3 27.3 27.3 27.2 28.0 27.3 
1’    61.8 70.1 70.4 75.5 75.7 78.9 62.2 70.5 75.8 79.3  
2’     15.0 15.2 135.9 136.0 28.0  15.2 135.9 28.0  
3’       117.6 117.5    117.6   
a
 To facilitate the comparison of NMR data of the Beckman product 4 and the parental oxime ethers we 162 
applied the steroid atomic numbering also for compound 4.  163 
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Table 2. 1H chemical shift, multiplicities and coupling constants of compounds 2, 4, 11-15 in methanol-d4. 164 
No.  2 J (Hz) 4
a
 J (Hz) 11 J (Hz)
b 
12 13 14 15 
1 α 1.98 dd; 14.0, 6.5 2.19 dd; 14.0, 6.8 1.95 dd; 13.9, 6.3 1.94 1.95 1.92 1.98 
 β 1.25  1.30  1.26  1.28 1.28 1.29 1.25 
2  4.19 ddd; 11.0, 6.5, 4.5 4.25 ddd; 12.0, 6.8, 5.0 4.18 ddd; 10.8, 6.3, 4.5 4.19 4.19 4.19 4.19 
3  4.26 td; 4.5, 1.7 4.39 dt; 5.0, 3.0 4.24 td; 4.5, 1.2 4.25 4.25 4.24 4.27 
4 α 1.77  1.29  1.60  1.60 1.61 1.57 1.77 
 β 1.97  2.06  2.10  2.11 2.14 2.11 1.95 
5  2.25 dd; 12.1, 4.2 3.30 dd; 10.2, 6.5 3.14 dd; 12.8, 4.6 3.15 3.19 3.15 2.26 
7  6.81 d; 2.7 5.94 d; 2.6 6.14 d; 2.6 6.16 6.16 6.20 6.70 
9  2.27  2.37 ddd; 11.5, 3.6, 2.6 2.31  2.31 2.31 2.29 2.24 
11 α 1.65  1.88  1.63  1.63 1.62 1.61 1.64 
 β 1.72  1.74  1.68  1.68 1.67 1.67 1.71 
12 α 1.53  1.60  1.50  1.50 1.50 1.50 1.52 
 β 2.23  2.21  2.22 dt; 12.7, 3.0 2.22 2.22 2.22 2.22 
15  5.86 dd; 3.5, 2.0 5.74 dd; 3.5, 1.9 5.81 dd; 3.3, 2.1 5.81 5.81 5.79 5.82 
16 α 2.33  2.33  2.32  2.32 2.31 2.31 2.32 
 β 2.60  2.58  2.58  2.58 2.58 2.58 2.59 
17  2.04 dd; 10.7, 7.7 2.11 dd; 10.7, 7.8 2.02 dd; 10.8, 7.7 2.02 2.02 2.01 2.03 
18  1.06  1.06  1.05  1.05 1.05 1.05 1.05 
19  0.83  0.96  0.84  0.84 0.85 0.84 0.81 
21  1.22  1.21  1.22  1.22 1.22 1.22 1.22 
22  3.76  3.75  3.76  3.76 3.76 3.77 3.76 
23 a 1.53  1.53  1.53  1.53 1.53 1.53 1.54 
 b 1.53  1.53  1.53  1.53 1.53 1.53 1.54 
24 a 1.48  1.48  1.48  1.48 1.48 1.48 1.48 
 b 1.72  1.72  1.72  1.72 1.72 1.72 1.72 
26  1.20  1.20  1.19  1.19 1.19 1.19 1.19 
27  1.21  1.21  1.21  1.20 1.20 1.21 1.21 
28Meα  1.30  1.30  1.31  1.31 1.31 1.32 1.32 
28Meβ  1.47  1.46  1.49  1.49 1.49 1.50 1.49 
29Meα  1.40  1.40  1.40  1.40 1.40 1.40 1.40 
29Meβ  1.30  1.30  1.30  1.30 1.30 1.30 1.31 
1’      3.86  4.11 4.56 - - 
2’        1.27 6.00 1.29 1.29 
3’ Z        5.19   
 E        5.29   
 165 
a
 To facilitate the comparison of NMR data of the Beckman product 4 and the parental oximethers we 166 
applied also for 4 the steroide atomic numbering. 167 
b Because the stereostucture of the steroid frame is nearly identical within compounds 11-15 we described 168 
the J coupling contants only for 11. 169 
 170 
  171 
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Table 3. 1H chemical shifts, multiplicities and coupling constants of compounds 5-10 in methanol-d4. 172 
No.  5 J (Hz)
a 
6 7 8 9 10 
1 α 1.98  1.98 1.94 1.98 1.95 1.98 
 β 1.22  1.23 1.24 1.23 1.24 1.23 
2  4.21 ddd; 10.5, 6.7, 5.1 4.21 4.21 4.22 4.21 4.22 
3  4.28  4.28 4.26 4.28 4.27 4.28 
4 α 1.93  1.93 1.73 1.93 1.74 1.92 
 β 1.93  1.93 2.06 1.93 2.08 1.92 
5  2.22 dd; 12.2, 5.5 2.23 3.16 2.24 3.19 2.26 
7  6.44 d; 2.7 6.47 5.88 6.49 5.88 6.47 
9  2.72 ddd; 11.8, 6.9, 2.7 2.71 2.72 2.72 2.73 2.70 
11 α 1.65  1.65 1.65 1.64 1.63 1.64 
 β 1.59  1.58 1.58 1.59 1.58 1.59 
12 α 2.03 td; 12.0, 5.5 2.04 2.04 2.04 2.04 2.03 
 β 1.80 dm; 12.0 1.81 1.80 1.81 1.80 1.80 
15 α 1.61  1.62 1.63 1.62 1.63 1.62 
 β 1.96  1.97 1.94 1.97 1.94 1.96 
16 α 1.85  1.85 1.85 1.86 1.85 1.85 
 β 2.00  2.00 2.02 2.01 2.02 2.02 
17  2.28 dd; 9.1, 7.8 2.28 2.27 2.29 2.27 2.28 
18  0.80  0.81 0.81 0.81 0.81 0.81 
19  0.83  0.83 0.84 0.83 0.85 0.82 
21  1.17  1.17 1.17 1.17 1.17 1.17 
22  3.68  3.68 3.68 3.68 3.68 3.68 
23 a 1.52  1.52 1.52 1.52 1.52 1.52 
 b 1.52  1.52 1.52 1.52 1.52 1.52 
24 a 1.48  1.48 1.49 1.48 1.49 1.49 
 b 1.73  1.73 1.73 1.73 1.73 1.74 
26  1.19  1.19 1.19 1.19 1.19 1.19 
27  1.20  1.20 1.20 1.20 1.20 1.20 
28Meα  1.31  1.31 1.32 1.31 1.32 1.32 
28Meβ  1.47  1.47 1.50 1.47 1.49 1.49 
29Meα  1.39  1.39 1.39 1.39 1.39 1.39 
29Meβ  1.32  1.32 1.32 1.32 1.32 1.32 
1’  3.82  4.07 4.10 4.53 4.55 - 
2’    1.25 1.26 5.98 5.99 1.28 
3’ Z     5.18 5.19  
 E     5.26 5.28  
a Because the stereo-structure of the steroid frame is nearly identical within this set of compounds, the J 173 
coupling constants are given only once. 174 
 175 
It is well known that oximation of ketones is accompanied with characteristic changes of several 176 
13C and 1H chemical shifts. Successful conversion of a C=O group to C=N-OH results of ca. 50 177 
ppm diamagnetic shift of the corresponding carbon atom, whereas the chemical shift of α-CH 178 
carbon atom in the syn position with respect to the oxime hydroxyl group exhibits ~14 ppm , in 179 
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the anti position ~9 ppm diamagnetic shift. The significant (∆δ syn-anti) parameters on C−5 and 180 
=C-7 signals successfully can be utilised for the assignment of (Z/E) isomers. Galyautdinov et al. 181 
reported some NMR data on 20-hydroxyecdysone oxime,[22] including compound 3 (Z isomer), 182 
but they failed on isolating the isomeric compound 2 with Z configuration. In addition they have 183 
taken the NMR measurements in solvents with rather different anisotropic nature (e.g. pyridine-184 
d5, methanol-d4) and so in some cases the solvation effect was comparable with the ∆δ syn-anti 185 
parameters. To avoid this ambiguity, we have performed our NMR experiments exclusively in 186 
methanol-d4.  187 
On the basis of our data, all of the oxime derivatives in Table 1 with δC-5 ~ 38.6 and δC-7 ~ 188 
117.5 ppm values, respectively, are Z isomers, while δC-5 ~ 43.8 and δC-7 ~ 111.0 ppm values 189 
assign the E isomers. It is worth noting that the less different δC-4 (~30/27 ppm) and δC-6 190 
(~157/161 ppm) values also reflect on the E or Z isomers, respectively.  191 
In case of compounds 2 and 4, and the 6-oxime-ether derivatives 11–15 the DEPTQ and HSQC 192 
measurements revealed only seven methylene groups, one less than in the parent compound 1, 193 
and simultaneously distinctive chemical shift changes appeared at δC-14: 85.4→C= ~142 ppm 194 
and δΗ2C-15: 31.8→HC= ~124 ppm, respectively, indicating the emergence of an ∆14,15 C=CH 195 
ethylene moiety. All this means that in these compounds (2, 11–15), simultaneously with the 196 
oximation, dehydration by the elimination of the 14-OH group also took place. The presence of 197 
the 14-OH substituent in compounds 5-10 appears straightforward, considering of the chemical 198 
shift of C-14 (δC-14 ~85 ppm) confirmed by the HMBC cross-peak H3-18/C-14. Success of the 199 
Beckmann rearrangement of ecdysteroid (6E)-oxime 2 into lactam 4 could be expected from the 200 
E configuration of the parent oxime. Indeed, the significant (13.1 ppm) paramagnetic shift on δC-201 
5 proves that in 4 the nitrogen atom coupled to C-5, the appearance of the signal at 170.6 ppm 202 
supports the formation of the lactam ring. 203 
Thanks to the comprehensive one- and two-dimensional NMR techniques utilized in the structure 204 
elucidation process, a complete 1H signal assignment could be achieved for all compounds. The 205 
characteristic 1H NMR data of the 14,15-anhydro derivatives 2, 4 and 11-15 are summarized in 206 
table 2, whereas that of the other compounds 5-10 in table 3. The main difference between the 207 
two sets of data is that in Table 2, besides H-7, a second olefinic signal appears for H-15 (~δ5.80 208 
dd) instead of the H2-16 hydrogen signals.  209 
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The retained cis junction of the A/B rings in each compound was obvious by considering the 210 
strong H3-19/Hβ-5 ROESY response, whereas the assignment of the α/β position of the 211 
diastereotopic methylene hydrogens of the skeleton were revealed by the one-dimensional 212 
selective ROESY measurements irradiating e.g. the H3-18, H3-19 and H-5 atoms in combination 213 
with the observed proton-proton coupling pattern.  214 
Considering the data of table 2 and 3 it is clear that the values of δH-5 and δH-7 chemical shifts 215 
allow the easy and unequivocal differentiation between the E and Z isomers. In case of the 14,15-216 
anhydro derivatives 2 and 11-15, the H-5 signals resonate around 2.25 ppm in the E and at 3.15 217 
ppm in the Z isomers, and the δH-7 chemical shifts appear at 6.76 ppm in the E and at 6.16 ppm 218 
in Z isomers. Similar trend was observed for the compounds in Table 3, the chemical shift of H-5 219 
in the anti position with respect to the oxime hydroxyl group exhibits ~2.23 ppm, while in the Z 220 
isomer it is ~3.18 ppm. The corresponding values for H-7 are 6.45 and 5.88 ppm, respectively.  221 
To facilitate the comparison between the NMR data of Z and E isomeric pairs, the stereo-222 
structures with atomic numbering (in red) of compounds 7 (upper) and 6 (lower) are shown in 223 
Figure 2. Blue numbers refer to 1H chemical shifts; black numbers give the δ 13C values. 224 
 225 
Figure 2. Characteristic NMR spectra on differentiation and NMR assignments of the isomeric 6 226 
and 7 ecdysteroid 6-oxime ethers are given in the supporting information.  227 
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Biology 228 
Antiproliferative activity of compounds 4-15 was tested on a panel of gynecological cancer cell 229 
lines, including cervical (HeLa, SiHa) and breast cancer cancer cell lines (MDA-MB-231, 230 
MCF7); the results are presented in Table 4.  231 
 232 
Table 4. Antiproliferative properties of compounds 4-15 against four human gynecological 233 
cancer cell lines. Inhibition concentration at 50% growth (IC50) values of each compound and the 234 
95% confidence intervals are given for each cell line. 235 
 IC50 (µM)  
Compound HeLa SiHa MDA-MB-231 MCF7 
4 >30 >30 >30 >30 
5 >30 >30 >30 >30 
6 >30 >30 >30 22.55 [17.24–29.50] 
7 29.12 [24.00–32.94] >30 25.12 [17.74–35.57] 13.10 [10.89–15.77] 
8 15.55 [13.69–17.66] 25.52 [21.95–29.68] 21.36 [18.86–24.19] 13.63 [11.91–15.60] 
9 17.55 [14.77–20.84] >30 26.90 [23.34–31.00] 17.22 [15.21–19.50] 
10 8.43 [4.66–9.29] 16.13 [13.02–19.99] 12.36 [11.00–13.89] 11.06 [9.96–12.29] 
11 15.43 [12.87–18.50] >30 25.99 [21.67–29.50] 18.03 [15.86–20.50] 
12 29.96 [27.03–33.20] >30 26.00 [23.44–28.85] 19.59 [17.09–22.46] 
13 >30 >30 29.37 [26.11–33.03] 24.16 [20.36–28.68] 
14 20.71 [18.63–23.02] 8.14 [5.62–11.79] 15.70 [13.50–18.25] 17.29 [15.33–19.52] 
15 26.06 [22.45–30.25] 14.17 [10.60–18.94] 16.93 [14.71–19.49] 19.34 [16.51–22.66] 
Cisplatin 14.02 [12.65–15.56] 7.87 [5.83–10.63] 18.65 [16.67–20.85] 6.01 [5.33–6.79] 
 236 
Although most of the ecdysteroid analogs displayed moderate activities against the tested cell 237 
lines, the i-butyl substituted compound 10 was stronger than the positive control cisplatin on the 238 
HeLa and MDA-MB-231 cell lines. In our previous study, the antiproliferative IC50 values of 239 
compound 1 were 106.1 and 75.1 µM on the MDA-MB-231 and MCF7 cell lines, respectively,[21] 240 
showing that the inclusion of certain oxime ether functions can increase this activity by nearly an 241 
order of magnitude. While the orientation of the oxime ether had no obvious effect on the 242 
activity, a larger alkyl group led to a stronger antiproliferative action. It appears to be clear that 243 
the retained 14-OH function is favorable over the ∆14,15 moiety in this regard on the MCF-7 cell 244 
line (compounds 7 vs. 12, 9 vs. 13, and 10 vs. 15), while such a conclusion cannot be drawn on 245 
the other cell lines. 246 
Compounds 2-15 were also tested for their cytotoxic activity on a murine lymphoma cell line 247 
pair, including L5178 and its multi-drug resistant counterpart transfected to express the human 248 
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ABCB1 transporter, L5178MDR. Following this, the compounds were tested for their potential to 249 
inhibit the ABCB1 efflux transporter through measuring the intracellular accumulation of 250 
rhodamine 123 by flow cytometry. Degree of inhibition (%) values were calculated by means of 251 
the rhodamine 123 accumulation of the ABCB1 transfected L5178MDR cells (i.e. 0 % inhibition) 252 
and that of the L5178 cells (i.e. 100% inhibition); results are presented in Table 5. 253 
 254 
Table 5. Cytotoxicity of compounds 1-15 on L5178 and L5178MDR cells, and functional 255 
inhibition of the ABCB1 transporter. Dox=doxorubicin; for the ABCB1 inhibition, positive 256 
control: 100 nM of tariquidar (112.4% inhibition), negative control: 2% DMSO (-0.07% 257 
inhibition). 258 
 Change in the 14-OH or IC50 (µM) [95% confidence intervals] b ABCB1 inhibition (%) 
Compound B-ring of 1
 a 
Δ
14,15 L5178 L5178MDR 2 µM 20 µM 
1
 
- 14-OH 110.3 [77.50-157.1] 97.69 [71.07-134.3] 2.54 20.91 
2 (E)-oxime Δ
14,15
 20.91 [17.68-24.74] 24.63 [19.82-30.63] 10.57 82.95 
3 (Z)-oxime Δ
14,15
 34.22 [28.21-41.51] 28.35 [21.97-36.58] 7.15 81.09 
4 δ-lactam Δ
14,15
 63.42 [47.51-84.65] 72.35 [64.39-81.29] 1.16 4.27 
5 (E); R=Me 14-OH 40.92 [35.66-46.97] 55.05 [41.53-72.98] 2.25 25.05 
6 (E); R=Et 14-OH 35.02 [25.35-48.38] 47.00 [31.14-70.93] 17.54 78.79 
7 (Z); R=Et 14-OH 37.26 [25.65-54.11] 42.16 [41.24-43.10] 18.96 75.03 
8 (E); R=Allyl 14-OH 31.48 [23.71-41.80] 51.91 [42.69-63.13] 20.98 89.39 
9 (Z); R=Allyl 14-OH 36.66 [28.32-47.44] 49.29 [43.07-56.40] 24.17 81.80 
10 (E); R=t-But 14-OH 28.06 [21.30-36.98] 29.12 [25.12-33.76] 38.75 112.4 
11 (Z); R=Me Δ
14,15
 45.95 [36.97-57.11] 53.14 [43.54-64.86] 33.36 106.2 
12 (Z); R=Et Δ
14,15
 53.20 [38.64-73.26] 58.94 [45.86-75.74] 56.41 107.7 
13 (Z); R=Allyl Δ
14,15
 55.28 [46.21-66.13] 52.72 [39.97-65.53] 61.13 102.7 
14 (Z); R=t-But Δ
14,15
 63.23 [58.57-68.26] 51.22 [39.13-67.04] 58.99 78.76 
15 (E); R=t-But Δ
14,15
 63.84 [45.70-89.19] 65.44 [55.66-76.94] 67.46 93.95 
Dox - - 0.080 [0.053-0.12] 4.49 [3.43-5.89] - - 
a
 R groups refer to the alkyl substituents of the oxime ethers as in Scheme 1 259 
b
 IC50 values were calculated by the CompuSyn software as the median cytotoxic activities (Dm) 260 
from the control lanes on the checkerboard plates of the combination studies, n=2. 261 
 262 
While the compounds also exerted weak to moderate cytotoxic activities on the mouse lymphoma 263 
cell line pair, all of them were more potent than their parental compound 1. No cross resistance 264 
was observed to any of them on the ABCB1 over-expressing MDR cells. The oximes 2 and 3 265 
showed the strongest activity on either cell lines with IC50 values ca. 4-5 times below that of 266 
compound 1, and the E-oxime (2) was more cytotoxic than the Z-oxime (3). The oxime ethers 267 
typically exerted weaker cytotoxic activities than the non-substituted oximes, with the exception 268 
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of compound 10 where a bulky t-butyl substituent and a retained 14-OH group were present. 269 
When comparing corresponding analogs with a retained 14-OH group or a ∆14,15 moiety, there 270 
appeared to be a clear tendency for the former structural element to be associated with a stronger 271 
cytotoxic activity on the mouse lymphoma cells, similarly to the case of MCF-7 cells (see above). 272 
Evaluation of the results obtained from the rhodamine accumulation assay reveals that the lactam 273 
derivative (4) is the only one among the compounds that was completely inactive in this regard at 274 
as much as 20 µM concentration. For the other compounds, several structure-activity 275 
relationships could be observed. The oxime formation markedly increased the ABCB1 inhibitory 276 
activity, and this was particularly true for oxime ethers. The orientation of the oxime group had 277 
little if any influence on the ABCB1 inhibition (compound 2 vs. 3, 6 vs. 7, 8 vs. 9, and 14 vs. 15), 278 
while the 14-OH elimination, forming a ∆14,15 double bond in the ecdysteroid D-ring, clearly 279 
increased this activity (compound 7 vs. 12, 9 vs. 13, and 10 vs. 15). When comparing the activity 280 
of oximes and oxime ethers between analogs containing the same type of D-ring and orientation 281 
of oxime but different substituents on the latter, the following order of bioactivity could be 282 
concluded: H < Me < Et < Allyl ≤ t-But. 283 
The compounds were also tested for their ability to sensitize the susceptible/resistant mouse 284 
lymphoma cell line pair towards the cytotoxic activity of doxorubicin. Since each compound 285 
showed a measurable cytotoxic activity on both cell lines when applied alone, combination 286 
indices could be determined through the checkerboard microplate method similarly to our 287 
previous related studies.[17][19] Table 6 shows the strongest activity observed for each compound 288 
on the L5178
 
and L5178MDR cell lines; further details and results at other compound:doxorubicin 289 
ratios are available in supporting information Table S1.  290 
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Table 6. Chemo-sensitizing activity of compounds 1-15 on the L5178
 
and L5178MDR cell lines 291 
towards doxorubicin at 50, 75 and 90% of growth inhibition (ED50, ED75 and ED90, respectively). 292 
CI: combination index; CIavg: weighted average CI value; CIavg = (CI50 + 2CI75 + 3CI90)/6. CI < 1, 293 
CI = 1, and CI > 1 represent synergism, additivity, and antagonism, respectively. Dm, m, and r 294 
represent antilog of the x-intercept, slope, and linear correlation coefficient of the median-effect 295 
plot, respectively. 296 
        CI at           
Compound Cell line Drug 
ratio ED50 ED75 ED90 Dm m r CIavg 
1 [21] L5178MDR 20.4 : 1 0.27 0.14 0.07 11.678 3.246 0.964 0.13 
  
L5178 163 : 1 0.67 0.55 0.46 11.236 2.103 0.942 0.53 
2 L5178MDR 15 : 1 0.26 0.16 0.12 4.454 6.638 1.000 0.16 
  
L5178 150 : 1 0.80 0.79 0.78 10.748 2.572 0.997 0.78 
3 L5178MDR 30 : 1 0.32 0.25 0.20 7.595 3.981 0.994 0.24 
  
L5178 150 : 1 0.98 0.76 0.61 16.049 3.239 0.986 0.72 
4 L5178MDR 15 : 1 0.20 0.12 0.09 6.419 4.953 0.970 0.12 
  
L5178 150 : 1 0.40 0.42 0.46 10.477 2.033 0.966 0.44 
5 L5178MDR 15 : 1 0.17 0.16 0.16 6.605 3.721 0.978 0.16 
  
L5178 150 : 1 1.06 0.79 0.62 14.306 2.947 0.971 0.75 
6 L5178MDR 7.5 : 1 0.18 0.14 0.12 5.001 5.858 1.000 0.14 
  
L5178 37.5 : 1 0.55 0.58 0.60 8.598 2.495 0.972 0.59 
7 L5178MDR 3.75 : 1 0.27 0.16 0.13 3.030 3.329 0.993 0.16 
  
L5178 37.5 : 1 0.63 0.52 0.45 8.078 3.858 0.952 0.50 
8 L5178MDR 15 : 1 0.17 0.13 0.13 4.939 3.193 0.955 0.14 
  
L5178 150 :1 1.03 0.81 0.69 8.970 2.178 0.991 0.79 
9 L5178MDR 15 : 1 0.17 0.16 0.17 7.338 3.771 0.947 0.17 
  
L5178 75 : 1 0.70 0.83 1.03 8.202 1.722 0.956 0.91 
10 L5178MDR 7.5 : 1 0.30 0.20 0.17 3.928 4.610 1.000 0.20 
  
L5178 37.5 : 1 0.58 0.63 0.70 7.606 2.502 0.966 0.66 
11 L5178MDR 7.5 : 1 0.17 0.16 0.15 5.224 3.722 0.971 0.16 
  
L5178 37.5 : 1 0.77 0.47 0.31 8.165 3.044 0.982 0.44 
12 L5178MDR 7.5 : 1 0.21 0.14 0.11 6.133 4.890 0.992 0.14 
  
L5178 75 : 1 0.49 0.50 0.52 7.864 2.094 0.961 0.51 
13 L5178MDR 3.75 : 1 0.25 0.15 0.11 5.614 5.805 1.000 0.15 
  
L5178 37.5 : 1 0.46 0.47 0.47 8.295 2.882 0.981 0.47 
14 L5178MDR 7.5 : 1 0.34 0.26 0.23 8.365 3.378 0.939 0.26 
  
L5178 37.5 : 1 0.53 0.59 0.66 9.652 2.400 0.961 0.62 
15 L5178MDR 7.5 : 1 0.27 0.24 0.23 8.739 3.813 0.960 0.24 
  L5178 37.5 : 1 1.16 0.85 0.64 7.199 3.273 0.977 0.80 
 297 
All tested derivatives showed strong synergism (0.1< CIavg <0.3)[25] with doxorubicin on the P-gp 298 
expressing L5178MDR cells, similarly to their parental compound (1). As it was previously 299 
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reported by us, chemo-sensitizing activity of ecdysteroids has little if any correlation to their 300 
(most typically weak) inhibitory effect on the efflux function of P-gp.[20] This was clearly 301 
confirmed in the present study as well: even though for example compounds 11-15 are much 302 
stronger P-gp inhibitors than their parental compound 1, no difference can be observed in the 303 
strength of synergism with the P-gp substrate doxorubicin on the MDR cell line. Most 304 
interestingly, among all derivatives obtained, the ecdysteroid lactam 4 was found to express the 305 
strongest chemosensitization on the MDR cells, while being the only one to show no interference 306 
with P-gp function. Accordingly, this compound has a further advantage over the diacetonide of 307 
20E, namely that it would likely be free from the potential adverse effects and unwanted drug-308 
drug interactions connected to P-gp inhibitors.[26][27] 309 
Considering structure-activity relationships, the several highly active compounds obtained in this 310 
work led us to follow our previously applied “best ratio” principle.[17] This means that we aimed 311 
to compare the compounds’ chemo-sensitizing activities at their strongest, regardless of the 312 
compound vs. doxorubicin ratio where this activity was observed. 313 
The length or nature of the alkyl function had no apparent effect on the compounds potency in 314 
sensitizing the MDR cells to doxorubicin, all compounds showed similarly high activity in this 315 
regard. A slight tendency may be observed for the ∆14,15 compounds (2-4, 11-15) acting stronger 316 
in this regard than their corresponding analogs where the 14-OH group was retained (5-10), but 317 
the differences are so small that it is hard to make a sound judgment on the relevance of this 318 
phenomenon. 319 
On the other hand, larger differences were observed between the compounds’ activities on the 320 
non-MDR L5178 cells. On this cell line, the strongest synergism with doxorubicin was observed 321 
for the lactam (4) and compound 11, a methyl substituted ∆14,15 (Z)-oxime ether. The oxime 322 
formation together with the elimination of the 14-OH group (2 and 3) decreased the strength of 323 
synergism with doxorubicin as compared to the case of compound 1. In case of the oxime ethers, 324 
the 14,15-anhydro derivatives typically exerted stronger sensitizing activity to doxorubicin than 325 
their analogs with intact 14-OH groups, except for compounds 10 vs. 15. Since oxime ethers 326 
substituted with bulky t-buthyl groups seem to show a tendency for decreased activity as 327 
compared to the corresponding analogs with ethyl groups (6 vs 10 and 12 vs. 14), one could 328 
hypothesize that the effect of the t-butyl group in the oxime ether function may overwrite that of 329 
the ∆14,15 moiety in compound 15. 330 
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 331 
Conclusions 332 
The present study reports the preparation and in vitro pharmacological investigation of 14 333 
ecdysteroid diacetonide oximes, oxime ethers and a lactam, with 13 novel derivatives obtained in 334 
pure form for the first time. The synthetic procedure was utilized in a way to obtain product 335 
mixtures in order to increase chemical diversity, and subsequent use of high-performance 336 
separation techniques allowed us to obtain the compounds in high purity. All compounds are 337 
reported with a complete NMR signal assignment.  338 
Evaluation of the antiproliferative and cytotoxic activity of the compounds on several cancer cell 339 
lines revealed several structure-activity relationships (SAR). A new, i-butyl substituted 340 
ecdysteroid oxime ether (10) was found to exert stronger antiproliferative effect on HeLa cells 341 
than cisplatin. The ∆14,15 E-oxime derivative (2) exerted a substantially increased cytotoxic and P-342 
gp inhibitory activities in the L5178/L5178MDR cell line pair, as compared to its parental 343 
compound. 344 
Clear SAR was observed for the compounds’ activity as functional P-gp inhibitors, and many of 345 
them were identified as highly potent MDR-selective chemo-sensitizers. In particularly, a novel 346 
∆14,15 δ-lactam ecdysteroid derivative (4) was revealed as a most promising new lead compound 347 
with low intrinsic cytotoxicity, and strong ability to sensitize MDR and also non-MDR cancer 348 
cells towards doxorubicin without interfering with the efflux function of P-gp. Accordingly, it 349 
can be expected that a combined treatment of cancer with this compound as a chemo-sensitizer 350 
and a chemotherapeutic agent would 1) be effective on the initial, susceptible state of the tumor, 351 
and 2) have a strong chance to prevent the acquisition of P-gp mediated resistance through an 352 
increased killing effect on the cell population becoming adapted to the chemotherapy. 353 
 354 
Experimental section 355 
Chemistry 356 
All applied reagents were purchased from Sigma (Sigma-Aldrich Co., USA). Solvents were 357 
obtained from Macron Fine Chemicals (Avantor Performance Materials, USA). 358 
1H (500.1 MHz) and 13C (125.6 MHz) NMR spectra were recorded at room temperature on a 359 
Bruker Avance-II spectrometer and on Avance-III spectrometer equipped with a cryo probehead. 360 
Regarding the compounds, amounts of approximately 1 - 10 mg were dissolved in 0.1 mL of 361 
methanol-d4 and transferred to 2.5 mm Bruker MATCH NMR sample tube. Chemical shifts are 362 
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given on the δ-scale and are referenced to the solvent (MeOH-d4: δC = 49.1 and δH = 3.31 ppm). 363 
Pulse programs of all experiments (1H, 13C, DEPTQ, DEPT-135, one-dimensional sel-ROE 364 
(mixing time: 300 ms), edited gs-HSQC and gs-HMBC) were taken from the Bruker software 365 
library. The NMR signals of the product were assigned by comprehensive one- and two-366 
dimensional NMR methods using widely accepted strategies.[28][29][30]Most 1H assignments were 367 
accomplished using general knowledge of chemical shift dispersion with the aid of the proton-368 
proton coupling pattern (1H NMR spectra). Mass spectra were obtained on a Waters Acquity 369 
iClass UPLC coupled with Thermo Q Exactive Plus with HESI source (Waters Co., USA). 370 
Reaction progress was monitored by thin layer chromatography (TLC) on Kieselgel 60F254 silica 371 
plates obtained from Merck (Merck, Germany), and examined under UV illumination at 254 nm. 372 
Compounds were purified by flash chromatography with adequately chosen eluents of n-hexane – 373 
dichloromethane – methanol on 12 g RediSep NP-silica flash columns (TELEDYNE Isco, USA). 374 
For the RP-HPLC separation of isomeric oxime derivatives a Kinetex XB-C18 250 x 21.4 mm 5 375 
µm preparative (Phenomenex Inc., USA) or an Agilent Eclipse XDB-C8 250 x 9.4 mm 5 µm 376 
semi-preparative column (Agilent Technologies Inc., USA) was applied with the use of isocratic 377 
grade eluents of acetonitrile and water. Purity of obtained compounds was determined by RP-378 
HPLC with the use of a Kinetex XB-C18 250 x 4.6 mm 5 µm analytical column (Phenomenex 379 
Inc., USA). For data collection a Jasco HPLC instrument equipped with an MD-2010 Plus PDA 380 
detector (Jasco Analytical Instruments, Japan) was applied in a detection range of 210-400 nm. 381 
Ecdysteroid substrate 1 was synthesized from 20-hydroxyecdysone (20E) obtained from Shaanxi 382 
KingsSci Biotechnology Co., Ltd. (Shanghai, People’s Republic of China) at 90% purity and was 383 
recrystallized (EtOAc:MeOH – 2:1) to a RP-HPLC purity of 97.8%. During the synthetic 384 
procedure, 20E (10g) is dissolved in acetone in the concentration of g/100 cm3 and 385 
phospomolybdic acid is added (10g) under stirring. After 5 minutes of stirring at RT the reaction 386 
is complete and the mixture is neutralized with 10% aqueous NaHCO3. Acetone is evaporated 387 
under reduced pressure and the mixture is extracted with EtOAc (3x50 ml) followed by drying 388 
with Na2SO4. After filtration, solvent is evaporated under reduced pressure and the crude mixture 389 
is purified by flash chromatography with isocratic grade eluents of dichloromethane:methanol – 390 
99:1. (Yield: 51%) 391 
Synthesis of ecdysteroid 6-oximes (2-3). 1g 1 (1,78 mmol) was dissolved in pyridine (10 ml) 392 
and 1 g hydroxylamine hydrochloride (14.39 mmol) was added to the solution under stirring. 393 
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After 3 days of stirring at 70°C the reaction was complete and the solvent was evaporated under 394 
reduced pressure. Following water addition (50 ml), the mixture was extracted with EtOAc (3x50 395 
ml) and the combined organic phase was dried with Na2SO4. A filtration was made to remove 396 
drying agent and the solvent was evaporated under reduced pressure. Purification of the crude 397 
mixture was carried out by preparative RP-HPLC to obtain (E/Z)-isomeric oximes 2-3, 398 
respectively. 399 
Synthesis of ecdysteroid lactam derivative (4). 0.138 g oxime 2 (0,25 mmol) was dissolved in 400 
anhydrous acetone (10 ml), then 0.027 g Na2CO3 (0.25 mmol) and 0.096 g p-toluenesulfonyl 401 
chloride  (0,5 mmol) was added to the solution under stirring. After 6 hours of stirring at RT, the 402 
reaction was stopped and the mixture was cooled to 0°C. Under stirring, water (10 ml) was added 403 
and the mixture was extracted into ethyl acetate (3x50 ml). After evaporation under reduced 404 
pressure, the mixture was purified with semi-preparative RP-HPLC to obtain lactam derivative 4. 405 
General Procedure for the synthesis of ecdysteroid 6-oxime ethers (5-15). 200 mg 1 (0,35 406 
mmol) was dissolved in pyridine (8 ml) and depending on the oxime ether to be obtained, 200 mg 407 
alkoxyamine-hydrochloride was added to the solution under stirring.  After stirring at 70°C for 24 408 
hours, the mixture was cooled down to 0°C, neutralized with KOH dissolved in anhydrous 409 
methanol and evaporated under reduced pressure. Water (50 ml) was added and the mixture was 410 
extracted with EtOAc (3x50 ml). The combined layers were dried with Na2SO4 and after 411 
filtration, the organic solvent was evaporated under reduced pressure. Purification of crude 412 
material was carried out by flash chromatography on silica gel to obtain compounds 5-15, 413 
respectively. In cases of oxime pairs 2-3, 6-7, 8-9, 14-15 preparative RP-HPLC was applied to 414 
separate the isomeric oxime and oxime ether derivatives. 415 
 416 
Compound 4: White solid; yield: 8% (11.04mg); RP-HPLC purity: 98.1%; for 1H- and 13C-417 
NMR data, see Tables 2 and 3, respectively; HR-HESI-MS: C33H52O6N, calcd. 558.3789, found: 418 
558.3737. 419 
Compound 5: White solid; yield: 28.3% (59.53mg); RP-HPLC purity: 99.8%; for 1H- and 13C-420 
NMR data, see Tables 1 and 3, respectively; HR-HESI-MS: C34H56O7N, calcd. 590.4051, found: 421 
590.4045. 422 
Compound 6: White solid; yield: 15.2% (32.75 mg); RP-HPLC purity: 99.6%; for 1H- and 13C-423 
NMR data, see Tables 1 and 3, respectively; HR-HESI-MS: C35H58O7N, calcd. 604.4208, found: 424 
604.4198. 425 
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Compound 7: White solid; yield: 2.8% (6.06 mg); RP-HPLC purity: 98.7%; for 1H- and 13C-426 
NMR data, see Tables 1 and 3, respectively; HR-HESI-MS: C35H58O7N, calcd. 604.4208, found: 427 
604.4199. 428 
Compound 8: White solid; yield: 15.5% (34.05 mg); RP-HPLC purity: 98.3%; for 1H- and 13C-429 
NMR data, see Tables 1 and 3, respectively; HR-HESI-MS: C36H58O7N, calcd. 616.4208, found: 430 
616.4201. 431 
Compound 9: White solid; yield: 1.6% (3.5 mg); RP-HPLC purity: 99.6%; for 1H- and 13C-NMR 432 
data, see Tables 1 and 3, respectively; HR-HESI-MS: C36H58O7N, calcd. 616.4208, found: 433 
616.4200. 434 
Compound 10: White solid; yield: 38.9% (87.67 mg); RP-HPLC purity: 98.5%; for 1H- and 13C-435 
NMR data, see Tables 1 and 3, respectively; HR-HESI-MS: C37H62O7N, calcd. 632.4521, found: 436 
632.4515. 437 
Compound 11: White solid; yield: 43.3% (88.32 mg); RP-HPLC purity: 97.7%; for 1H- and 13C-438 
NMR data, see Tables 2 and 3, respectively; HR-HESI-MS: C34H54O6N, calcd. 572.3946, found: 439 
572.3937. 440 
Compound 12: White solid; yield: 33.3% (69.59 mg); RP-HPLC purity: 97.5%; for 1H- and 13C-441 
NMR data, see Tables 2 and 3, respectively; HR-HESI-MS: C35H56O6N, calcd. 586.4102, found: 442 
586.4099. 443 
Compound 13: White solid; yield: 2% (4.25 mg); RP-HPLC purity: 98.3%; for 1H- and 13C-444 
NMR data, see Tables 2 and 3, respectively; HR-HESI-MS: C36H56O6N, calcd. 598.4102, found: 445 
598.4094. 446 
Compound 14: White solid; yield: 8.3% (18.17 mg); RP-HPLC purity: 98.7%; for 1H- and 13C-447 
NMR data, see Tables 2 and 3, respectively; HR-HESI-MS: C37H60O6N, calcd. 614.4415, found: 448 
614.4411. 449 
Compound 15: White solid; yield: 2.5% (5.48 mg); RP-HPLC purity: 95.8%; for 1H- and 13C-450 
NMR data, see Tables 2 and 3, respectively; HR-HESI-MS: C37H60O6N, calcd. 614.4415, found: 451 
614.4407. 452 
 453 
Biology 454 
Cell cultures. The human gynecological cancer cell lines MDA-MB-231 and MCF7 (breast 455 
cancers), and HeLa (cervical adenocarcinoma) were purchased from ECACC (European 456 
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Collection of Cell Cultures, Salisbury, UK), while SiHa (cervical carcinoma) was purchased from 457 
ATCC (American Tissue Culture Collection, Manassas, Virginia, USA). The cells were grown in 458 
Minimum Essential Medium (MEM) supplemented with 10% fetal calf serum (FCS), 1% non-459 
essential aminoacids, and 1% penicillin-streptomycin. All media and supplements for these 460 
experiments were obtained from Lonza Group Ltd. (Basel, Switzerland). The cells were 461 
maintained at 37 ⁰C in humidified atmosphere containing 5% CO2. Two mouse lymphoma cell 462 
lines were also used: a drug susceptible cell line, L5178 mouse T-cell lymphoma (ECACC 463 
catalog number 87111908, U.S. FDA, Silver Spring,MD, U.S.), and its multidrug resistant 464 
counterpart (L5178MDR) obtained by transfection with pHa MDR1/A retrovirus.[31] Cells were 465 
cultured in McCoy’s 5A media supplemented with nystatin, L-glutamine, penicillin, 466 
streptomycin, and inactivated horse serum, at 37∘C and 5% CO2. The MDR cell line was selected 467 
by culturing the infected cells with 60 g/L colchicine (Sigma). Media, fetal bovine serum, horse 468 
serum, and antibiotics were purchased from Sigma. 469 
 470 
Antiproliferative assay on human gynecological cancer cell lines. The growth-inhibitory 471 
activities of the prepared ecdysteroid analogs were determined by the MTT (3-(4,5-472 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method on four human adherent cancer 473 
cell lines of gynecological origin.[32] Briefly, cells were seeded into 96 well plates (5000 474 
cells/well) and incubated with increasing concentrations of the tested compounds (0.1–30.0 µM) 475 
under cell-culturing conditions. After incubation for 72 h, 5 mg/ml MTT solution was added and 476 
the samples were incubated for another 4 h. The precipitated formazan crystals than were 477 
dissolved in dimethyl sulfoxide and the absorbance was measured at 545 nm with a microplate 478 
reader. Cisplatin, a clinically used anticancer agent was used as a positive control. In order to 479 
calculate fifty percent inhibitory concentrations (IC50), sigmoidal dose–response curves were 480 
fitted to the measured points by using the non-linear regression model log (inhibitor) vs. 481 
normalized response and variable slope with a least squares (ordinary) fit of GraphPad Prism 5.01 482 
software (GraphPad Software Inc., San Diego, CA, USA). 483 
 484 
Cytotoxicity assay on murine lymphoma cell lines. Cytotoxic activities on the L5178 and 485 
L5178MDR cell lines were performed as described before.[18] Briefly, 5 x 104 cells/well were 486 
incubated with serial dilutions of each compound (n = 3) in McCoy’s 5 A medium (Sigma-487 
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Aldrich) for 48 h at 37°C, 5% CO2. Then, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 488 
bromide (MTT, Sigma) was added to each well at a final concentration of 0.5 mg/mL per well 489 
and after 4 h of incubation, 100 µL of sodium dodecyl sulfate (SDS) 10% (Sigma-Aldrich) in 490 
0.01 M HCl was added to each well. Plates were further incubated overnight, the optical densities 491 
were read at 540 and 630 nm using an ELISA reader (Multiskan EX, Thermo Labsystem, 492 
Milford, MA, USA), and IC50 values were calculated as described above. 493 
 494 
Rhodamine 123 accumulation assay. ABCB1 inhibitory activities of the compounds were 495 
studied through their effect on the accumulation of rhodamine 123, a fluorescent dye that is an 496 
ABCB1 substrate. Flow cytometry was used as described before.[17] Briefly, 2 x 106 cells/mL 497 
were treated with 2 or 20 µM of each compound. After 10 min incubation, rhodamine 123 498 
(Sigma-Aldrich) was added to a final concentration of 5.2 µM and the samples were incubated at 499 
37 °C in a water bath for 20 min. Samples were centrifuged (Heraeus Labofuge 400, Thermo 500 
Fisher Scientific, Waltham, MA, USA) (2000 rpm, 2 min) and washed twice with phosphate 501 
buffer saline (PBS, Sigma). The final samples were re-suspended in 0.5 mL PBS and its 502 
fluorescence measured with a Partec CyFlow flow cytometer (Partec, Münster, Germany). 100 503 
nM of tariquidar was used as positive control, which was kindly provided by Dr. Milica Pesic 504 
from the Institute for Biological Research Sinisa Stankovic, Belgrade, Serbia. 505 
 506 
Cytotoxicity assay in combination with doxorubicin. The checkerboard microplate method 507 
was utilized to test the combined activity of doxorubicin (Teva, Budapest, Hungary) and the 508 
ecdysteroid derivatives on the L5178 and L5178MDR cell lines, as described before.[17] Briefly, 5 × 509 
104 cells/well were incubated with doxorubicin and the compound to be tested in McCoy’s 5 A 510 
medium (Sigma-Aldrich) for 48 h at 37°C, 5% CO2. Then, 3-(4,5-dimethylthiazol-2-yl)-2,5-511 
diphenyltetrazolium bromide (MTT, Sigma) was added to each well at a final concentration of 512 
0.5 mg/mL per well, and after 4 h of incubation, 100 µL of sodium dodecyl sulfate (SDS) 10% 513 
(Sigma-Aldrich) in 0.01 M HCl was added to each well. The plates were further incubated 514 
overnight, and the optical densities were read at 540 and 630 nm using an ELISA reader 515 
(Multiskan EX, Thermo Labsystem, Milford, MA, USA). The interaction was evaluated using the 516 
CompuSyn software (CompuSyn Inc., Paramus, NJ, USA) at each constant ratio of compound vs. 517 
doxorubicin (M/M), and combination index (CI) values were obtained for 50%, 75%, and 90% of 518 
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growth inhibition. Single-drug data obtained from the duplicate control lanes of each plate were 519 
utilized to determine cytotoxic activities for each compound. 520 
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